Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
Medical University of Lodz
Łódź, PoloniaPublikationen in Zusammenarbeit mit Forschern von Medical University of Lodz (7)
2023
-
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70
2022
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83
2020
-
Should breast reconstruction and breast oncoplastic procedures be performed during the coronavirus pandemic?
ecancermedicalscience, Vol. 14
2019
-
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794
2014
-
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Blood, Vol. 123, Núm. 26, pp. 4136-4142
2011
-
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial
British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221